About Contact Us Careers

Advanced Therapy Medicinal Products Market Size and Forecast, by Product (CAR-T Therapy, Gene Therapy, Cell Therapy, Tissue Engineered Product); Disease (Oncology, Genetic Disorder, CNS, Dermatology); End-user (Hospitals & Clinics, Research & Academic Institutes) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 4684
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT
  1. Introduction
    1. Market Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. Distributors
      3. End Users
    3. Secondary Research
    4. Market Size Estimation
  4. Executive Summary – Global Advanced Therapy Medicinal Products Market
  5. Analysis of Market Dynamics
    1. Drivers
    2. Trends
  6. Key Market Opportunities for Business Growth
  7. Major Roadblocks for the Market Growth
  8. Regulatory & Standard Landscape
  9. Value Chain Analysis
  10. Potential ATMP Treatment Analysis
  11. Pricing Analysis of Global Advanced Therapy Medicinal Products Market
  12. Use Case Analysis
  13. Pipeline Analysis
  14. Analysis on the Manufacturing Process
  15. Analysis of COVID-19 Impact on the Global Advanced Therapy Medicinal Products Market
  16. Analysis of End-User Market Share of Global Advanced Therapy Medicinal Products
  17. Competitive Positioning
  18. Competitive Landscape
    1. Market Share Analysis of Major Players (%), 2021
    2. Competitive Benchmarking
      1. Novartis AG.
      2. Takeda Pharmaceutical Company Limited
      3. Gilead Sciences, Inc.
      4. Bluebird Bio, Inc
      5. BioMarin Pharmaceutical Inc
      6. Vericel Corporation
      7. Mallinckrodt Pharmaceuticals
      8. UniQure N.V.
      9. JCR Pharmaceuticals Co., Ltd.
      10. Spark Therapeutics, Inc. (Parent Company: Roche)
      11. Kolon TissueGene, Inc. 
  19. Global Advanced Therapy Medicinal Products Market Outlook
    1. By Value (USD million)
    2. By Product
      1. CAR-T Therapy, 2023-2036F (USD million)
      2. Gene Therapy, 2023-2036F (USD million)
      3. Cell Therapy, 2023-2036F (USD million)
      4. Tissue Engineered Product, 2023-2036F (USD million)
    3. By Disease
      1. Oncology, 2023-2036F (USD million)
      2. Genetic Disorders, 2023-2036F (USD million)
      3. CNS, 2023-2036F (USD million)
      4. Dermatology, 2023-2036F (USD million)
      5. Others, 2023-2036F (USD million)
    4. By End-User
      1. Hospitals & Clinics, 2023-2036F (USD million)
      2. Research & Academic Institutes, 2023-2036F (USD million)
    5. Global Advanced Therapy Medicinal Products Market by Region
      1. North America, 2023-2036F (USD million)
      2. Europe, 2023-2036F (USD million)
      3. Asia-Pacific, 2023-2036F (USD million)
      4. Latin America, 2023-2036F (USD million)
      5. Middle East & Africa, 2023-2036F (USD million)
  20. North America Advanced Therapy Medicinal Products Market Outlook
    1. By Value (USD million)
    2. By Product
      1. CAR-T Therapy, 2023-2036F (USD million
      2. Gene Therapy, 2023-2036F (USD million)
      3. Cell Therapy, 2023-2036F (USD million)
      4. Tissue Engineered Product, 2023-2036F (USD million)
    3. By Disease
      1. Oncology, 2023-2036F (USD million)
      2. Genetic Disorders, 2023-2036F (USD million)
      3. CNS, 2023-2036F (USD million)
      4. Dermatology, 2023-2036F (USD million)
      5. Others, 2023-2036F (USD million)
    4. By End-User
      1. Hospitals & Clinics, 2023-2036F (USD million)
      2. Research & Academic Institutes, 2023-2036F (USD million)
    5. By Country
      1. US, 2023-2036F (USD million)
      2. Canada, 2023-2036F (USD million)
  21. Europe Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. UK, 2023-2036F (USD Million)
      2. Germany, 2023-2036F (USD Million)
      3. France, 2023-2036F (USD Million)
      4. Italy, 2023-2036F (USD Million)
      5. Spain, 2023-2036F (USD Million)
      6. Russia, 2023-2036F (USD Million)
      7. Netherlands, 2023-2036F (USD Million)
      8. Rest of Europe, 2023-2036F (USD Million)
  22. Asia Pacific Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. China, 2023-2036F (USD Million)
      2. India, 2023-2036F (USD Million)
      3. Japan, 2023-2036F (USD Million)
      4. South Korea, 2023-2036F (USD Million)
      5. Singapore, 2023-2036F (USD Million)
      6. Australia, 2023-2036F (USD Million)
      7. Rest of Asia-Pacific, 2023-2036F (USD Million)
  23. Latin America Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. Brazil, 2023-2036F (USD Million)
      2. Argentina, 2023-2036F (USD Million)
      3. Mexico, 2023-2036F (USD Million)
      4. Rest of Latin America, 2023-2036F (USD Million)
  24. Middle East & Africa Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. GCC, 2023-2036F (USD Million)
      2. Israel, 2023-2036F (USD Million)
      3. South Africa, 2023-2036F (USD Million)
      4. Rest of Middle East & Africa, 2023-2036F (USD Million)

 

Advanced Therapy Medicinal Products Market Outlook:

Advanced Therapy Medicinal Products Market size was valued at USD 45.2 billion in 2025 and is likely to cross USD 175.06 billion by 2035, expanding at more than 14.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of advanced therapy medicinal products is assessed at USD 51.1 billion.

Advanced-Therapy-Medicinal-Products-Market-scope
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The growth of the market can be attributed to the increased prevalence of the genetic disorder. Drugs used in gene therapy are advanced therapy medicinal products that contain genes that have therapeutic, preventative, or diagnostic effects. Recombinant genes are inserted into the body to cure a number of illnesses, such as cancer, genetic problems, and chronic diseases. For instance, all over the world around 300 million people are living with a rare disease and it affects nearly 4% to 6% of the total world population.

In addition to these, factors that are believed to fuel the growth of the advanced therapy medicinal products market include higher adoption of gene therapy. Gene therapy is known to be one of the advanced therapy medicinal products. The therapy is used to treat the underlying genetic disorder by correcting the faulty gene in the body.  In one study, 93 percent of respondents supported the use of gene therapy to treat Leber congenital amaurosis, an inherited form of blindness, while just 35 percent said it was certainly okay to use it to improve memory. Furthermore, advanced therapy medicinal products are used to replace or restore dopamine transmission in various parts of the nervous system. Therefore, increased cases of neurological ailment are anticipated the higher projection of the advanced therapy medicinal products market.  According to the Pan American Health Organization’s 2019 statistics, around 7.5 million people are living with a neurological disorder and 533,172 deaths are due to the neurological condition.

Key Advanced Therapy Medicinal Products Market Insights Summary:

  • Regional Highlights:

    • North America advanced therapy medicinal products market is predicted to capture 44% share by 2035, driven by higher cases of cancer and neurological disorders and private investment.

  • Segment Insights:

    • The gene therapy segment in the advanced therapy medicinal products market is expected to grow at a healthy CAGR over 2026-2035, attributed to increasing clinical trials and a growing number of patients needing gene therapy.
    • The dermatology segment in the advanced therapy medicinal products market is forecasted to achieve the highest market share by 2035, supported by rising cases of skin problems and cancer worldwide.

  • Key Growth Trends:

    • Rising Problems of Genetic Diseases
    • Increase in Neurological Disorders

  • Major Challenges:

    • Restrictions for biopharmaceutical businesses to produce these treatments
    • Improper reimbursement assessment in medical products for advanced therapy

  • Key Players: Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.

Global Advanced Therapy Medicinal Products Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 45.2 billion
    • 2026 Market Size: USD 51.1 billion
    • Projected Market Size: USD 175.06 billion by 2035
    • Growth Forecasts: 14.5% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (44% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, Germany, Japan, United Kingdom, China
    • Emerging Countries: China, India, Japan, South Korea, Malaysia

    • Last updated on : 10 September, 2025

Growth Drivers

  • Rising Problems of Genetic Diseases - An illness characterized by one or more anomalies in the genome is referred to as a genetic condition. Advanced therapy medicinal products are one of the most effective ways to treat genetic disorder. According to the World Health Organization, around 2%–5% of all live births are affected by genetic illnesses and congenital anomalies, which can also be responsible for up to 50% of infant fatalities and 30% of pediatric hospital admissions in developed nations.
  • Increase in Neurological Disorders - Neurological disorder has become more prevalent among the people. People are getting affected by dementia, Alzheimer’s disease and others. As per the statistics of the United Nations, every year around 6.8 million people die of maladies, moreover, every 1 in 6th person is suffering from a neurological disorder.
  • Higher Demand for Gene Therapy - Gene therapy is used to replace the faulty gene and add the fit gene to the body. this procedure helps in fighting various diseases, such as cancer, AIDS, diabetes, and others. The number of people to be treated by gene therapy is estimated to be around 1 million from the year 2020 to 2035.
  • Growing Investment in Advanced Therapy Medicinal Products - With the increase in investment in the market, the research and development of advanced therapy medicinal products are also rising. In 202o, around USD 360 million were invested in cell therapy alone, and by 2021 it grew to nearly USD 70 billion.
  • Rise in the Development of New and Better Solutions - By the reports of the World Economic Forum, currently, there are more than 2000 advanced therapies in the development stage, and they are expected to treat larger pool of diseases.

Challenges

  • Advanced therapy medicinal products are not cost-effective- Advanced therapy medicinal products are typically highly customized or catered to a certain group of patients. As a result, it is challenging to automate or conform to good manufacturing standards in their manufacturing to achieve commercialization at an affordable level. Therefore, the high cost of the products is to hamper the market growth.
  • Restrictions for biopharmaceutical businesses to produce these treatments
  • Improper reimbursement assessment in medical products for advanced therapy

Advanced Therapy Medicinal Products Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

14.5%

Base Year Market Size (2025)

USD 45.2 billion

Forecast Year Market Size (2035)

USD 175.06 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Advanced Therapy Medicinal Products Market Segmentation:

Disease Segment Analysis

The dermatology segment is to garner the highest advanced therapy medicinal products market revenue at the end of 2035. The segment growth is expected on the back of rising cases of skin problems and cancer in the world. According to the World Health Organization, currently, 132,000 cases of melanoma and 2 to 3 million cases of non-melanoma skin cancer are reported annually worldwide. Skin cancer accounts for one in three cancer diagnoses, and one in five Americans will have it at some point in their lives.

Product Segment Analysis

The gene therapy segment is expected to grow at healthy CAGR over the forecast period. The segment growth is expected on the back of a higher number of people in need of gene therapy and growing clinical trials of gene therapy. By 2035, gene therapies could be used to treat more than 1 million Americans. Furthermore, in 2022, around 1221 cell and gene therapies are under active clinical trials, moreover, out of them nearly 324 clinical trials are in the phase of 1/1b.

Our in-depth analysis of the global market includes the following segments:

          By Product
  • CAR-T Therapy
  • Gene Therapy
  • Cell Therapy
  • Tissue Engineered Product

               By Disease
  • Oncology
  • Genetic Disorder
  • CNS
  • Dermatology
  • Others

                By End User
  • Hospitals & Clinics
  • Research & Academic Institutes
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Advanced Therapy Medicinal Products Market Regional Analysis:

North American Market Insights

The North America advanced therapy medicinal products market, amongst the market in all the other regions, is projected to hold the largest industry share of 44% by 2035. The market growth in North America is attributed to higher cases of cancer and neurological disorder followed by investment by private companies for the development of advanced therapy medicinal products. In 2022, around 600,000 deaths are attributed to the cancer cases and nearly 2 million new cases of cancer were diagnosed in the United States. Furthermore, in 2019, Pfizer Inc. a leading U.S. based pharmaceutical company announced the investment of USD 500 million to expand the gene therapy manufacturing unit in Sanford, North Carolina.

Advanced-Therapy-Medicinal-Products-Market-Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Advanced Therapy Medicinal Products Market Players:

    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Bluebird Bio, Inc.
    • BioMarin Pharmaceuticals Inc.
    • Vericel Corporation
    • Mallinckrodt Pharmaceuticals
    • UniQure N.V.
    • JCR Pharmaceuticals Co., Ltd.
    • Spark Therapeutics, Inc.
    • Kolon TissueGene,Inc.

Recent Developments

  • Novartis AG in collaboration with Medicines for Malaria Venture announced the entry of novel ganaplacide/lumenfantrine-SDF into the phase 3 study. This novel is a combination to treat uncomplicated malaria in both adults and children.

  • Takeda Pharmaceutical Company Limited announced the collaboration and licensing agreement with Zedira and Dr.Falk Pharma for the development of first in class Celiac disease therapy. It is a serious autoimmune disease, in which intake of gluten damages the small intestine.

  • Report ID: 4684
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of advanced therapy medicinal products is assessed at USD 51.1 billion.

The global advanced therapy medicinal products market size was valued at over USD 45.2 billion in 2025 and is expected to expand at a CAGR of over 14.5%, surpassing USD 175.06 billion revenue by 2035.

North America advanced therapy medicinal products market is predicted to capture 44% share by 2035, driven by higher cases of cancer and neurological disorders and private investment.

Key players in the market include Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.

Advanced Therapy Medicinal Products Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos